Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17), Briefing.com reports. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the prior year, the business earned ($0.20) earnings per share. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% on a year-over-year basis.

Kiniksa Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ KNSA traded up $0.08 during trading hours on Wednesday, hitting $23.34. 223,268 shares of the company traded hands, compared to its average volume of 411,868. Kiniksa Pharmaceuticals has a 12 month low of $14.12 and a 12 month high of $28.15. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -146.19 and a beta of 0.33. The company's 50 day moving average price is $25.64 and its 200 day moving average price is $22.42.

Analysts Set New Price Targets

Several brokerages recently weighed in on KNSA. Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a "buy" rating and a $40.00 target price for the company. Finally, Wedbush boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $34.60.

Insider Buying and Selling

In other news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Eben Tessari sold 17,500 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the transaction, the chief operating officer now owns 119,911 shares of the company's stock, valued at $3,226,805.01. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 112,692 shares of company stock valued at $2,950,315. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.